The S&P 600 trades at roughly 16x earnings. The S&P 500 trades at 23x. That gap of 7 turns is not noise, and it is not a rounding error from a few unprofitable biotech names. It is the widest valuation discount small caps have carried in over a decade, and it exists at the same time consensus projects small-cap earnings growth of 17 to 22 percent in 2026. I think institutional investors who treat this as a real allocation opportunity, rather than a seasonal flicker, are reading the earnings data correctly.
The P/E Trick That Muddies the Picture
Critics will point out that the Russell 2000's P/E balloons to roughly 37x once you include loss-making companies. That number is real, and it deserves respect. But using it to condemn the entire small-cap asset class is like valuing the S&P 500 based only on its worst quartile of earners. The S&P 600, which screens out persistent money-losers, gives you a much cleaner read on what you are actually buying. At 15.5 to 16x, that index sits near or below its own 10-year median while the S&P 500 sits well above its own.
For a pension fund or endowment allocating $10 million, the math is blunt: every dollar buys roughly 44% more earnings in the S&P 600 than in the S&P 500. Over a 2-year compounding window, that gap is hard to close even if large caps grow earnings at 12 to 14 percent.
Mark Hulbert at MarketWatch has argued that small-cap outperformance in early 2026 reflects seasonal factors with no predictive power for the rest of the year. Fair point; January effects and tax-loss recovery are real mechanics. But seasonality does not explain a valuation discount that has persisted for years, or an earnings growth trajectory that flipped small caps from lagging in 2025 to leading in 2026 projections.
Earnings Growth Is Not a Narrative
The Russell 2000 has beaten the S&P 500 by more than 5 percentage points year-to-date through mid-March. The MSCI World Small Cap Index gained 9.86% through February, compared to 3.03% for the MSCI World Index. Those numbers matter less for what they say about momentum and more for what they confirm about fundamentals. Small-cap earnings are actually arriving.
Take a name like Betterware de Mexico. Projected earnings growth of 65% and sales growth of nearly 29% over the trailing 12 weeks, with a stock price that has risen 20.85% in the same period. That is earnings pulling price higher. Compare that to the extreme return dispersion at the speculative end: Nektar Therapeutics up 8,375% in a year on clinical-stage catalysts. Those lottery tickets exist in every corner of the market. They do not define the asset class.
The distinction I keep coming back to is the one between the Russell 2000, which includes everything, and the S&P 600, which enforces a profitability screen. Investors who lump them together are comparing a curated portfolio to a junk drawer. The quality small-cap universe is cheap, growing earnings faster than large caps, and trading at a discount that has no obvious structural justification beyond the inertia of a decade spent piling into mega-cap tech.
Yes, March brought volatility tied to Middle East tensions. Micro-caps are up 68% from their April 2025 lows and a pullback was overdue. A 5 to 8 percent drawdown from here would not change the thesis. It would improve entry prices. For an investor with a 12-to-24-month horizon, that is an invitation, not a warning.
Miles Lewis at Royce Investment Partners has characterized 2026 as the beginning of a regime shift toward small-cap quality and value. I think the regime shift is already visible in the numbers. The S&P 600 is earning its discount away one quarter at a time, and the market has not caught up.
Seven turns of earnings is a lot of skepticism baked into a price. I want to own the asset that has to prove less.
